How Plesha was paid
$0 in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Total |
|---|---|---|---|---|
| Scott PleshaChief Executive Officer | $0 | $0 | $0 | $0 |
| Francis Knuettel IIChief Financial Officer | $424,923 | $56,666 | $361,833 | $843,422 |
| Sai RangaraoChief Commercial Officer | $0 | $0 | $0 | $0 |
| Eric LangChief Medical Officer | $446,154 | $0 | $230,318 | $676,472 |
| Christian KopfliFormer Chief Executive Officer, Former Chief Strategy Officer, and Former Vice Chairman | $0 | $0 | $0 | $0 |
What changed and why
- Scott Plesha was appointed Chief Executive Officer on July 1, 2025 following the merger.
- $843KFrancis Knuettel II received total compensation of $843,422 for fiscal year 2024.
- $676KEric Lang received total compensation of $676,472 for fiscal year 2024 before his termination.
- $438KScott Plesha will receive an annual base salary of $438,000 under his post-merger employment agreement.
Other Pelthos Therapeutics proxy statements
- 2026 proxy statement
Scott M. Plesha paid $4.2M.
Filed Aug 18, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.